Sat.Jun 08, 2024 - Fri.Jun 14, 2024

article thumbnail

New lab space for early-stage life science businesses

Drug Discovery World

Discovery Park has opened CoLab, a new shared lab facility in the UK. In partnership with Canterbury Christ Church University, CoLab has been designed for early-stage life science businesses, providing flexible bench space in a coworking environment. Dr Cornelia Wilson, Senior Lecturer and Academic Laboratory Director at Canterbury Christ Church University, said: “Finding lab space is too often a blocker for promising life science spin outs and start-ups, and CoLab exists to solve this.

Science 147
article thumbnail

Some CRISPR screens may be missing cancer drug targets

Broad Institute

Some CRISPR screens may be missing cancer drug targets By Allessandra DiCorato June 14, 2024 Breadcrumb Home Some CRISPR screens may be missing cancer drug targets Current CRISPR guides don’t work equally well in cells from people of all ancestries, which could lead to false negative results. By Allessandra DiCorato June 14, 2024 Credit: Ricardo Job-Reese, Broad Communications CRISPR/Cas9 gene editing has made possible a multitude of biomedical experiments including studies that systematically t

Drugs 145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Scientists preserve DNA in an amber-like polymer

Science Daily: Pharmacology News

With their 'T-REX' method, researchers developed a glassy, amber-like polymer that can be used for long-term storage of DNA, such as entire human genomes or digital files such as photos.

DNA 130
article thumbnail

What to know about endometrial cancer

Antidote

Also known as endometrial carcinoma or uterine cancer, endometrial cancer occurs when the cells that line the uterus begin growing uncontrollably. Though the mortality rates are relatively low due to the high rate of early detection, it is a cancer that impacts nearly 70,000 people every year.

122
122
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Breakthrough drug discovery research collaboration in obesity

Drug Discovery World

Flagship Pioneering and ProFound Therapeutics have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. The collaboration is the first initiated under Flagship’s Pioneering Medicines strategic partnership with Pfizer announced in July 2023. Pioneering Medicines, Flagship’s in-house drug discovery and development unit, is responsible for leading the partnership with Pfizer, including driving the exp

Research 147
article thumbnail

Moderna Announces Good Results From Trial of Combo COVID/Flu Vaccine

Drugs.com

MONDAY, June 10, 2024 -- An experimental vaccine that could offer one-stop prevention for both COVID-19 and influenza is showing positive results among older adults in trials, maker Moderna announced Monday.The shot — for now called mRNA-1083 — "ha.

Vaccine 119

More Trending

article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

FDA Law Blog: Biosimilars

By Sara W. Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. The FTC has put out policy statements, challenged patent listings, tapped Congress, appeared on talk shows, and filed amicus briefs all in the span of the last 8 months. It seems like all that work is paying off.

FDA 116
article thumbnail

New DDW Highlights podcast: 11 June 2024

Drug Discovery World

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event.

Research 147
article thumbnail

FDA Tells Vaccine Makers to Target New COVID Variant for Fall

Drugs.com

FRIDAY, June 14, 2024 -- COVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot of the JN.1 variant that spread widely last winter, the U.S. Food and Drug Administration announced Thursday. It's a.

Vaccine 115
article thumbnail

Would astronauts' kidneys survive a roundtrip to Mars?

Science Daily: Pharmacology News

The structure and function of the kidneys is altered by space flight, with galactic radiation causing permanent damage that would jeopardise any mission to Mars, according to a new study led by researchers from UCL.

Research 122
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

BioPharma Drive: Drug Pricing

Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.

Drugs 112
article thumbnail

Researchers discover genetic cause of inflammatory bowel diseases

Drug Discovery World

Researchers have discovered a new biological pathway in inflammatory bowel disease (IBD) and related conditions that can be targeted using existing drugs. About 5% of the world’s population are currently affected by an autoimmune disease, such as IBD, the umbrella term for Crohn’s disease and ulcerative colitis. These diseases are also becoming more common, with over half a million people living with IBD in the UK as of 2022, nearly double the 300,000 previously estimated.

Disease 147
article thumbnail

'Dual Mutant' Seasonal Flu Virus Could Make Some Treatments Ineffective

Drugs.com

THURSDAY, June 13, 2024 -- Two human cases of "dual mutant" strains of H1N1 flu have been reported by U.S. health officials.Unfortunately, the genetic changes appear to render the leading flu antiviral, Tamiflu, less effective, researchers from the.

Virus 113
article thumbnail

AI-powered simulation training improves human performance in robotic exoskeletons

Science Daily: Pharmacology News

Researchers have demonstrated a new method that leverages artificial intelligence (AI) and computer simulations to train robotic exoskeletons to autonomously help users save energy while walking, running and climbing stairs.

Research 119
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

OTC Hearing Aids: “Nothing to See Here” Says GAO Report

FDA Law Blog: Biosimilars

By Sara W. Koblitz & Jeffrey N. Gibbs — It’s been over a year and a half since Over-the-Counter (“OTC”) hearing aids became legal, and it’s not clear that they’ve made the difference in hearing loss treatment that Congress anticipated. (FDA once estimated that OTC hearing aids would save patients over $3000.) A recent GAO Report hasn’t found that OTC hearing aids have had much impact.

FDA 111
article thumbnail

New Cardiff facility to manufacture organoids for drug discovery

Drug Discovery World

A new facility has opened in Cardiff, UK designed to manufacture patient-derived organoids (PDOs) at scale for use in drug discovery and development. The multi-million-pound facility was custom-built by Molecular Devices to house its bioprocess workflow and bioreactor technology Mary Duseau, President of Molecular Devices said: “With our new facility, we now have the capacity to manufacture 300 million PDOs annually.

Drugs 147
article thumbnail

ADHD Patients Could Face Disrupted Access to Meds Following Fraud Case

Drugs.com

FRIDAY, June 14, 2024 -- The two top officers of a telehealth company that began to distribute ADHD drugs widely during the pandemic have been charged with health care fraud, the U.S. Department of Justice announced Thursday. The arrests will.

Drugs 111
article thumbnail

Swimming microrobots deliver cancer-fighting drugs to metastatic lung tumors in mice

Science Daily: Pharmacology News

Engineers have developed microscopic robots, known as microrobots, capable of swimming through the lungs to deliver cancer-fighting medication directly to metastatic tumors. This approach has shown promise in mice, where it inhibited the growth and spread of tumors that had metastasized to the lungs, thereby boosting survival rates compared to control treatments.

article thumbnail

How long does a patent last for drugs?

Drug Patent Watch

Sure, here’s a more detailed explanation with examples: Drug Patent Duration Drug patents are granted by the United States Patent and Trademark Office (USPTO) for a period of 20 years… Source

Drugs 111
article thumbnail

US approves first mRNA vaccine since Covid-19

Drug Discovery World

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna. “The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform,” said Stéphane Bancel,

Vaccine 147
article thumbnail

Secondary Tumors After CAR-T Cancer Therapies Are Rare: Study

Drugs.com

THURSDAY, June 13, 2024 -- CAR-T cell therapy to treat blood cancers is safer than previously thought, with little risk that the immunotherapy will create secondary cancers, a new study finds.The U.S. Food and Drug Administration issued a warning.

Therapies 110
article thumbnail

Are mixed emotions real? New research says yes

Science Daily: Pharmacology News

Neuroscientists found that brains display distinct neural activity when experiencing emotions such as bitter-sweetness. The advance could help solve a longstanding scientific debate: whether 'mixed emotions' arise from unique activity in the brain, or if we're just flip-flopping back and forth between positive and negative feelings.

Research 116
article thumbnail

Knock, Knock – FDA Issues Guidance on Best Processes and Practices During BIMO Inspections

FDA Law Blog: Biosimilars

By Sarah Wicks & Anne K. Walsh — Among FDA-regulated establishments and stakeholders, there is one word that makes everyone go on edge – the dreaded FDA “inspection.” In an effort to clarify for industry and alleviate some of the stress associated with these activities, last week the FDA issued a draft guidance aimed at providing recommendations on how to handle inspections under FDA’s Bioresearch Monitoring (BIMO) program.

FDA 111
article thumbnail

This week in drug discovery (10-14 June) 

Drug Discovery World

News round-up for 10-14 June by DDW Senior Digital Content Editor Diana Spencer. With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation to CAR-T therapies. The top stories: Gene therapy restores hearing in both ears Five children who were born with congenital hearing loss can hear in both ears after taking part in a gene therap

Therapies 130
article thumbnail

Ipsen drug for rare liver disease approved by FDA

BioPharma Drive: Drug Pricing

The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.

Disease 111
article thumbnail

Tiny New Zealand bird delivers a lesson in birdsong evolution

Science Daily: Pharmacology News

Scientists are rethinking the evolution of vocal learning in birds. New Zealand's smallest bird, the rifleman or titipounamu, may have a rudimentary version of the talent possessed by parrots, hummingbirds and songbirds.

114
114
article thumbnail

Two-Drug Treatment Could Curb Meth Addiction

Drugs.com

MONDAY, June 10, 2024 — Though overdose deaths continue to surge, there is no approved medication to treat methamphetamine use disorder.Now, an experimental two-drug therapy has yielded promising results, UCLA researchers report."These findings h.

Treatment 111
article thumbnail

Metformin slows cancer growth using microRNAs, study finds

Drug Discovery World

Australian researchers have analysed how an antidiabetic treatment could help control the growth of tumours, potentially paving the way for the design of better cancer treatments. The new study investigated what happens when metformin, a type 2 diabetes medication, is used to treat colorectal cancer cells, in the process demonstrating that it could be exploited to develop new cancer therapies.

RNA 130
article thumbnail

Pfizer gene therapy for Duchenne fails to meet goals of key trial

BioPharma Drive: Drug Pricing

The negative results from the Phase 3 study, called Ciffreo, come a little more than a month after Pfizer said a patient died in another trial of the gene therapy.

Therapies 114
article thumbnail

Infectious H5N1 influenza virus in raw milk rapidly declines with heat treatment

Science Daily: Pharmacology News

The amount of infectious H5N1 influenza viruses in raw milk rapidly declined with heat treatment in laboratory research. However, small, detectable amounts of infectious virus remained in raw milk samples with high virus levels when treated at 72 degrees Celsius (161.6 degrees Fahrenheit) for 15 seconds -- one of the standard pasteurization methods used by the dairy industry.

Virus 107
article thumbnail

FDA Advisors Support New Alzheimer's Drug, Donanemab

Drugs.com

TUESDAY, June 11, 2024 -- A U.S. Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer's outweigh its harms, which can include brain swelling and bleeding. Eli Lilly's.

FDA 110
article thumbnail

Webinar: The latest innovative solutions in biotherapeutic manufacturing

Drug Discovery World

Join DDW and Thermo Fisher Scientific on 20 June, 11AM EDT/4PM BST, for an exclusive webinar, ‘ Advancing biotherapy manufacturing: innovative strategies for residual DNA and viral titre quantitation using dPCR ’. This free event will feature insight from Thermo Fisher Scientific’s Jonas Buege, Senior Manager, Product Management, as well as Viki Mahen, Scientist III, Molecular Biology.

DNA 130
article thumbnail

Regenxbio CEO to step down after 15 years

BioPharma Drive: Drug Pricing

Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

Therapies 104
article thumbnail

Pair plasmas found in deep space can now be generated in the lab

Science Daily: Pharmacology News

Researchers have experimentally generated high-density relativistic electron-positron pair-plasma beams by producing two to three orders of magnitude more pairs than previously reported.

Research 108